CrossBridge Bio, a biotechnology company pioneering next-generation dual-payload antibody-drug conjugates (ADCs) that have the potential to deliver safer, more durable responses for patients, including those resistant to approved ADC therapies, today announced it has been awarded a $15 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT). The award will support completion of IND-enabling activities and advancement of CBB-120, the company’s lead TROP-2 targeted TOP1i/ATRi dual-payload ADC, into first-in-human studies.

HOUSTON--(BUSINESS WIRE)--CrossBridge Bio, a biopharmaceutical company pioneering next-generation dual-payload antibody-drug conjugates (ADCs) that have the potential to deliver safer more durable responses in patients, including those resistant to approved ADC therapies, today announced that it has been named the Winner of “Best Drug Developer” at the 2025 World ADC Awards.